Better Buy: GW Pharmaceuticals vs. Cara Therapeutics

If you're looking for promising biotech stocks, there's plenty of options to choose from. Cara Therapeutics (NASDAQ: CARA) is a small-cap company that stayed strong for most of 2019 but has since given back a lot of its value. While it's fallen slightly out of favor, many experts still have high expectations for the stock.

On the other hand, GW Pharmaceuticals (NASDAQ: GWPH) is a larger drug developer that has been growing rapidly over the past year. Driven primarily by the explosive sales growth its cannabidiol (CBD) based drug, Epidiolex, GW Pharma has been a favorite among biotech and cannabis investors alike. However, the stock has lost a fair chunk of its value over the past six months despite its impressive revenue growth.

Which of these two stocks is a better buy today, you might ask?

Source Fool.com